Stammdaten
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. Nutriband Inc. has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
Unternehmen & Branche
| Name | NutriBand Inc. |
|---|---|
| Ticker | NTRB |
| CIK | 0001676047 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 3842 · Orthopedic, Prosthetic & Surgical Appliances & Supplies |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 45,7 Mio. USD |
| Beta | 1,93 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-10-31 | 10-Q | 346,058 | -3,872,367 | -0.32 | 8,419,160 | 7,548,952 |
| 2025-07-31 | 10-Q | 622,452 | -2,000,337 | -2.12 | 10,176,588 | 8,493,808 |
| 2025-04-30 | 10-Q | 667,432 | -1,388,869 | -0.12 | 6,152,181 | 5,103,386 |
| 2025-01-31 | 10-K | 2,139,537 | -10,482,617 | -0.99 | 7,469,955 | 6,428,905 |
| 2024-10-31 | 10-Q | 645,796 | -1,362,637 | -0.12 | 12,543,202 | 11,231,699 |
| 2024-07-31 | 10-Q | 442,830 | -1,705,465 | -0.15 | 13,633,709 | 12,460,986 |
| 2024-04-30 | 10-Q | 408,532 | -1,898,077 | -0.21 | 15,154,480 | 13,363,113 |
| 2024-01-31 | 10-K | 2,085,314 | -5,485,314 | -0.69 | 7,517,154 | 6,438,235 |
| 2023-10-31 | 10-Q | 427,841 | -1,759,946 | -0.22 | 8,523,076 | 5,711,338 |
| 2023-07-31 | 10-Q | 655,928 | -829,173 | -0.11 | 9,872,628 | 6,890,708 |
| 2023-04-30 | 10-Q | 476,932 | -1,015,229 | -0.13 | 8,675,702 | 7,719,881 |
| 2023-01-31 | 10-K | 2,079,609 | -4,483,474 | -0.53 | 9,456,377 | 8,572,990 |
| 2022-10-31 | 10-Q | 618,003 | -1,075,485 | -0.14 | 10,669,199 | 9,731,566 |
| 2022-07-31 | 10-Q | 456,149 | -1,038,675 | -0.12 | 11,387,072 | 10,401,830 |
| 2022-04-30 | 10-Q | 477,922 | -689,989 | -0.08 | 11,984,475 | 11,080,110 |
| 2022-01-31 | 10-K | 1,422,154 | -6,176,126 | -0.80 | 12,739,660 | 11,859,285 |
| 2021-10-31 | 10-Q | 283,037 | -1,571,821 | -0.23 | 15,427,751 | 14,318,875 |
| 2021-07-31 | 10-Q | 213,739 | -519,923 | -0.07 | 10,163,555 | 7,316,066 |
| 2021-04-30 | 10-Q | 433,488 | -315,957 | 10,560,120 | 7,835,989 | |
| 2021-01-31 | 10-K | 943,702 | -2,932,828 | 9,927,419 | 7,111,946 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.